Try searching for a clinical trial You can search by health conditions, keywords and trial or drug names

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents | Recruiting

This study will assess the safety and efficacy of secukinumab when added to a background
therapy in patients with active rheumatoid arthritis (RA) who are intolerant to or have had
an inadequate response to anti-tumor necrosis factor (TNF)-α agents.

This study will assess the safety and efficacy of secukinumab when added to a background
therapy in patients with active rheumatoid arthritis (RA) who are intolerant to or have had
an inadequate response to anti-tumor necrosis factor (TNF)-α agents.

A Randomized, Double-blind, Placebo-controlled Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Safety, Tolerability and Long Term Efficacy up to 2 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents.